CD40 and neoplasm: Some researchers have compared the agonizing efficacy of bivalent antibody with that of the hexavalent CD40 agonist HERA-CD40L, and found that the high-valent polymeric structure can significantly enhance receptor clustering and signaling activation, thereby enhancing the function of antigen-presenting cells and promoting anti-tumor immune responses (93).